trial

Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence

NCTId NCT00215579
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 64 (actual)
Sponsored by Duke University
Primary completion 2006-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
64 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2004-04
Primary completion
2006-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Duke UniversityLead Sponsor
Janssen, L.P. - Investigator Initiated Studies ProgramCollaborator

Investigators

1
William H Wilson, PhDPrincipal Investigator

Sites

1 total
Butner, United States

Facts & assertions

4 sourced
Enrollment
64
Phase
PHASE4
Primary Completion Date
2006-04
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Duke University
company
collaborator
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
William H Wilson, PhD
person